Evaluating Lifestyle Medicine in Real-World Vietnamese Healthcare: Study Designs, Implementation Outcomes, and Patient-Important Results

RESEARCH & IMPLEMENTATION

11/21/202630 min read

Evaluating Lifestyle Medicine in Real-World Vietnamese Healthcare: Study Designs, Implementation Outcomes, and Patient-Important Results

Last reviewed: November 21, 2026

Consider a Vietnamese outpatient clinic that introduces a structured Lifestyle Medicine program for adults with hypertension. Patients receive individualized dietary counseling, physical activity guidance, and regular follow-up alongside their usual medical treatment. Six months later, the clinical team reviews the results. Average blood pressure has declined, several patients report feeling healthier, and the staff believe the program has made a difference.

The findings are encouraging, but how much of the improvement can reasonably be attributed to the program?

Some patients may have had their medications adjusted during follow-up. Others may have become more consistent with existing treatment, received closer clinical monitoring, or changed their daily habits independently. Patients who completed the program may also differ from those who stopped attending. Even if the intervention contributed to better outcomes, its success in one clinic does not necessarily mean that another facility could achieve similar results with different patients, resources, and professional support.

These uncertainties illustrate an important challenge in evaluating Lifestyle Medicine under real-world healthcare conditions.

Scientific evidence supports the role of appropriate lifestyle interventions in preventing and managing many chronic conditions. However, the strength and directness of that evidence vary according to the intervention, condition, population, and outcome being examined. Evidence that a healthy behavior benefits health is not necessarily the same as evidence that a particular counseling strategy or clinical program can help patients adopt that behavior and achieve meaningful improvements.

A research agenda published in Family Medicine and Community Health in September 2025 emphasized the importance of stronger study designs, appropriate research methods, and meaningful outcomes when evaluating the effectiveness and implementation of Lifestyle Medicine. Developed through a hybrid Delphi process involving Dutch experts, the agenda also identified sustainable behavior change, biological mechanisms, and data infrastructure as priorities for further research.[1]

For Viet Nam, these questions have considerable practical relevance. Rather than simply repeating international studies on established lifestyle-related health risks, local research can help determine how evidence-based interventions perform within Vietnamese healthcare organizations, what patients experience, and which delivery models can be implemented safely and sustainably.

Not every hospital or clinic needs to conduct a large randomized trial. What matters is selecting an evaluation approach that answers a clearly defined question, recognizes the limitations of available evidence, and produces information that clinicians, patients, researchers, and healthcare leaders can use responsibly.

Start With the Question the Evaluation Needs to Answer

A common difficulty in healthcare evaluation is that different meanings of success are brought together under a single conclusion.

A clinical team may want to know whether patients improved after participating in a Lifestyle Medicine program. Researchers may be interested in whether the program produced better outcomes than an appropriate alternative. Hospital leadership may be concerned about staffing requirements, financial sustainability, and whether the service can operate within existing clinical workflows. Patients may place greater importance on whether the program helps them function better, manage symptoms, or reduce the burden of living with a chronic condition.

These questions are connected, but they are not interchangeable.

An evaluation documenting changes among program participants can describe what happened during a period of care. It may provide useful information about feasibility, participation, and observed clinical outcomes. However, a favorable change after an intervention does not, by itself, establish that the intervention caused that change.

Successful implementation does not guarantee clinical effectiveness either. A program may achieve high attendance, consistent documentation, and good adherence to its planned procedures without producing meaningful improvements in patient health. Conversely, an intervention supported by clinical evidence may produce disappointing results because too few eligible patients receive it or essential components are not delivered consistently.

Researchers should therefore distinguish between the clinical effects of an intervention, the outcomes of implementing it, and the influence of the healthcare environment.

The effect being estimated should also be clear. A study assessing the effect of offering a program to eligible patients answers a different question from one examining outcomes among patients who participate intensively. The distinction matters because participation and continued engagement may be influenced by characteristics that also affect health outcomes.

The United Kingdom Medical Research Council's updated framework for developing and evaluating complex interventions, published in 2021, offers a useful methodological foundation. It encourages researchers to consider not only whether an intervention works but also how it may work, how it interacts with its context, what resources it requires, and which questions are most relevant to decision-makers.[2]

Lifestyle Medicine programs frequently involve several interacting components, including clinical assessment, behavior-change counseling, professional interaction, multidisciplinary support, and adaptations to individual circumstances. Their evaluation should recognize this complexity without becoming unnecessarily elaborate.

A well-defined research question helps determine what evidence is needed, which methods are appropriate, and what conclusions can reasonably be drawn.

Define the Intervention Before Evaluating Its Effect

Two healthcare organizations may describe their services as Lifestyle Medicine programs while delivering substantially different interventions.

One clinic might provide a single consultation followed by educational materials. Another may offer repeated appointments, individualized nutrition counseling, physical activity support, structured behavior-change techniques, and multidisciplinary follow-up. A third may use group consultations, telephone contact, or digital monitoring to support patients over an extended period.

Although these programs may address similar lifestyle domains, they differ in intensity, duration, professional involvement, and the support available to patients. Such differences can influence both clinical outcomes and the feasibility of delivering the intervention elsewhere.

A study should therefore describe what patients actually received rather than relying on the general label of Lifestyle Medicine.

The Template for Intervention Description and Replication, commonly known as TIDieR, provides an established framework for reporting healthcare interventions in sufficient detail for others to understand and potentially reproduce them.[3]

For a structured nutrition intervention, researchers should describe how patients were assessed, who provided the counseling, what recommendations were made, how frequently consultations occurred, and what support patients could access between appointments. Important modifications during delivery should also be documented, together with information about whether essential components were implemented as intended.

Concurrent medical care deserves similar attention. Patients may continue receiving medications, undergo additional examinations, or be referred to other healthcare professionals. These activities may be clinically necessary and can influence the outcomes being measured.

The comparison condition must also be defined carefully. Reporting that one group received Lifestyle Medicine while another received usual care provides limited information when usual care differs significantly between facilities.

A hospital with an established chronic disease management pathway may already provide substantial lifestyle counseling. Another facility may offer relatively little structured support. The additional effect of a new program could differ depending on what patients would otherwise have received.

Clear intervention descriptions also help distinguish essential clinical functions from features that can reasonably be adapted.

For example, individualized risk assessment and appropriate clinical monitoring may need to remain consistent, while appointment schedules, educational materials, and communication methods may be adjusted to reflect local circumstances.

Adaptation is not necessarily poor implementation. The important issue is whether changes preserve the intervention's intended clinical functions, professional responsibilities, and patient safety.

Without a sufficiently clear description of what was delivered and what it was compared with, even favorable results can be difficult to interpret or apply elsewhere.

Why Improvement After an Intervention Does Not Prove Causation

Before-and-after evaluations are common in healthcare because they can often be conducted within existing clinical services. Investigators measure patients before an intervention begins, repeat the measurements afterward, and examine whether outcomes have changed.

This approach can provide useful information about local service performance. It may help organizations identify operational difficulties, monitor participation, and determine whether further investigation is warranted.

Its principal limitation is that observed changes may have several possible explanations.

Consider patients enrolled in a hypertension program after recording unusually high blood pressure measurements. When those measurements are repeated, some readings may move closer to the patients' typical values even without a meaningful treatment effect. This statistical phenomenon, known as regression to the mean, can contribute to an apparent improvement.

Medication adjustments may also influence blood pressure during follow-up. Patients receiving more frequent clinical contact may become more consistent with their existing treatment. Changes in staffing, medication availability, or other aspects of healthcare delivery may affect outcomes during the same period.

A simple before-and-after comparison cannot reliably separate these influences.

Patient selection introduces another difficulty. People who voluntarily join an intensive Lifestyle Medicine program may have greater motivation, stronger family support, more flexible working arrangements, or fewer practical barriers than those who do not participate.

If these characteristics also influence health outcomes, the observed benefits may partly reflect differences that existed before the program began.

Loss to follow-up can further distort the results. Patients who find the intervention difficult, experience limited benefit, or face competing responsibilities may stop attending. If the analysis includes only those who complete the program, it may produce an overly favorable picture.

These limitations do not make descriptive evaluations inappropriate. A clinic can reasonably report that average blood pressure declined among patients with available follow-up measurements. What it cannot automatically conclude is that the Lifestyle Medicine program caused the entire reduction.

Descriptive findings can still be valuable, especially during early implementation. However, when the central question concerns comparative effectiveness, researchers need a study design that provides a more credible basis for estimating what would have happened without the intervention.

Choosing a Study Design That Fits Routine Healthcare

There is no single research design suitable for every Lifestyle Medicine intervention. The appropriate approach depends on what is already known, the uncertainty being investigated, the clinical setting, available resources, and the ethical implications of the research.

An early evaluation may focus on feasibility. Investigators may need to establish whether eligible patients can be recruited, whether clinicians can deliver the planned intervention, whether follow-up is acceptable, and whether reliable data can be collected.

These studies can reveal weaknesses before substantial resources are committed to a larger evaluation. Their findings should be interpreted as evidence about feasibility rather than definitive evidence of effectiveness.

When the objective is to estimate the comparative effect of an intervention, randomized controlled trials can provide stronger protection against important sources of selection bias and confounding, provided randomization, outcome assessment, follow-up, and analysis are conducted appropriately.

For some Lifestyle Medicine programs, randomization can occur at the individual patient level. In other circumstances, randomizing clinics or healthcare teams may be more appropriate.

This is particularly relevant when the intervention changes professional behavior or clinical workflows. If the same clinicians provide care to patients assigned to different study groups, elements of the intervention may unintentionally be delivered to patients in the comparison group.

Cluster randomized trials can help address this problem, although they require additional statistical and operational planning. Outcomes among patients treated within the same facility may be correlated, and the design and analysis must account for that clustering. The number of participating facilities can be as important as the total number of enrolled patients.

Pragmatic trials are particularly relevant when researchers want to understand how an intervention performs under conditions closer to routine care.

The PRECIS-2 framework helps investigators consider how pragmatic or explanatory different elements of a trial are, including patient eligibility, recruitment, setting, delivery flexibility, follow-up, outcomes, and analysis.[4]

A pragmatic trial is not synonymous with an observational study. It may retain randomized allocation while allowing important aspects of healthcare delivery to reflect ordinary practice. Nor does describing a trial as pragmatic guarantee methodological quality.

Where randomization is impractical or inappropriate, carefully designed observational and quasi-experimental studies may provide useful evidence.

Controlled before-and-after studies compare changes in an intervention group with changes in an appropriate comparison group. Interrupted time-series studies examine repeated observations before and after implementation to assess whether the introduction of an intervention is associated with a change in outcome level or trend.

Interrupted time-series designs require an adequate sequence of observations and careful consideration of other events occurring around the time of implementation. A change observed after a program begins may have a different explanation if another clinical policy, staffing arrangement, or treatment pathway changed at approximately the same time.

Difference-in-differences methods can sometimes estimate intervention effects by comparing outcome changes between groups over time. Their credibility depends on assumptions about what would have occurred without the intervention, including whether the groups would otherwise have followed comparable underlying trends.

Researchers using these methods also need to consider changes in patient composition, concurrent interventions, seasonal variation, and differences in outcome measurement.

For observational comparative-effectiveness research, the target trial emulation approach provides another useful perspective. It encourages investigators to specify the hypothetical randomized trial they would ideally conduct, including eligibility criteria, treatment strategies, the start of follow-up, outcomes, and the analysis plan, before attempting to answer the question using observational data.[5]

This approach can make important design decisions more explicit and help researchers recognize problems such as inappropriate selection of participants, unclear treatment assignment, and inconsistent follow-up periods.

Statistical adjustment, matching, and propensity-score methods may help account for measured differences between groups. However, these methods cannot automatically remove unmeasured confounding or compensate for poorly defined intervention exposure.

Mixed-method approaches may also be valuable when quantitative findings need to be understood alongside interviews, observations, or other qualitative evidence about implementation. Qualitative findings can reveal barriers and experiences that are difficult to capture through clinical records alone, although they do not independently establish comparative clinical effectiveness.

The strongest study is not necessarily the most technically complicated. It is the study whose design can address the principal uncertainty, whose methods are scientifically and ethically defensible, and whose conclusions remain proportionate to the available evidence.

Clinical Effectiveness and Implementation Outcomes Must Be Distinguished

Even when an intervention is supported by sound clinical evidence, its performance can change when introduced into everyday healthcare.

A structured Lifestyle Medicine pathway for patients with type 2 diabetes may include individualized nutrition counseling, physical activity support, behavioral guidance, and scheduled clinical follow-up. The clinical question is whether the pathway produces better health outcomes than an appropriate comparator.

The implementation question is different. It concerns whether eligible patients are identified, referrals are completed, professionals have sufficient training, appointments occur as planned, and patients receive the intended support.

This distinction becomes clearer when the clinical intervention is separated from the strategy used to implement it.

Nutrition counseling may be part of the intervention itself. Staff training, revised referral procedures, electronic reminders, and audit feedback may be strategies designed to help the organization deliver that intervention consistently.

Effectiveness-implementation hybrid designs, described by Curran and colleagues, offer a way to study these two dimensions within the same research program.[6]

Depending on the principal research question, a hybrid study may primarily assess clinical effectiveness while exploring implementation, examine clinical and implementation questions more directly, or focus on an implementation strategy while monitoring relevant clinical outcomes.

Collecting both clinical and operational data does not automatically make an evaluation a hybrid study. The relationship between the questions should be considered during study planning.

Implementation research also uses outcomes that are distinct from clinical outcomes.

Proctor and colleagues established a widely used framework identifying acceptability, adoption, appropriateness, feasibility, fidelity, implementation cost, penetration, and sustainability as important implementation outcomes.[7]

These concepts describe different aspects of healthcare delivery. A program may be acceptable to patients but difficult for professionals to deliver. Clinicians may adopt a new pathway without consistently implementing its essential components. A service may operate successfully during a funded pilot but become difficult to sustain after additional support ends.

The RE-AIM framework offers another perspective by examining reach, effectiveness, adoption, implementation, and maintenance.[8]

The updated Consolidated Framework for Implementation Research, or CFIR, published in 2022, helps researchers investigate factors that influence implementation, including characteristics of the innovation, organizational and external settings, individuals, and implementation processes.[9]

These frameworks have related but different purposes. RE-AIM can help structure evaluation of program reach and impact, while CFIR can help investigate circumstances that support or obstruct implementation. Neither independently establishes the clinical effectiveness of an intervention.

For Vietnamese healthcare organizations, their practical value lies in understanding why a program may perform well in one setting but encounter difficulties elsewhere.

A large specialist hospital may have access to multidisciplinary professionals and structured follow-up systems. A smaller clinic may have fewer personnel, limited consultation time, or different financial arrangements. Digital support may be convenient for some patients while creating barriers for others.

These differences can influence the extent to which an intervention reaches patients, how consistently it is delivered, and whether favorable results can be reproduced.

Implementation findings may help explain observed clinical results, but they should not automatically be interpreted as proof of causal mechanisms. Establishing why an intervention produced a particular outcome usually requires stronger evidence than demonstrating that two events occurred together.

A clinically promising intervention that was poorly delivered may require a better implementation strategy. An intervention delivered consistently but producing little meaningful benefit may require reconsideration of its clinical value. Distinguishing these situations is essential when deciding whether a program should be modified, expanded, studied further, or discontinued.

Patient-Important Results Should Shape the Evaluation

Clinical evaluations often rely on laboratory values, physiological measurements, and other indicators that can be collected consistently.

Blood pressure, HbA1c, lipid concentrations, and body weight can be valuable measures of clinical change. Depending on the condition, they may also inform treatment decisions and future health-risk assessment.

However, not every measurable improvement has the same meaning for patients.

An intervention may improve a biomarker without producing noticeable benefits in symptoms, physical function, independence, or quality of life. Conversely, patients may experience meaningful improvements in daily functioning or well-being despite only modest changes in a selected physiological measure.

The choice of outcomes should therefore begin with the clinical question and the needs of the population being studied.

Patients and caregivers can contribute to identifying these priorities, particularly when an intervention requires significant changes in daily routines or affects employment, family responsibilities, or the burden of managing chronic illness.

Patient-reported outcome measures may help capture symptoms, function, and quality of life directly from patients. The instrument selected should be appropriate for the intended population and supported by evidence concerning its measurement properties.

A questionnaire developed in another country should not be assumed to have equivalent validity simply because it has been translated into Vietnamese. Where necessary, cultural adaptation and validation should be considered.

Researchers should also distinguish patient-reported health outcomes from satisfaction and preferences. A participant may appreciate a program's convenience without experiencing measurable clinical improvement. Another may find an intervention demanding while obtaining substantial health benefits.

Both perspectives are relevant, but they answer different questions.

Outcomes should be prioritized before data collection wherever possible. Selecting numerous measures and emphasizing only those that subsequently produce favorable results increases the risk of misleading conclusions.

For comparative effectiveness research, a prespecified primary outcome, relevant secondary outcomes, and an appropriate follow-up period can improve the clarity of the evaluation.

The duration of follow-up deserves particular attention in Lifestyle Medicine. Improvements observed shortly after an intervention may not persist when structured support ends. Understanding whether behavioral and clinical changes are maintained may therefore require longer observation, depending on the intervention and outcomes being investigated.

Researchers should also distinguish statistical significance from clinical importance.

A small difference may reach conventional statistical significance in a sufficiently large study while providing limited practical benefit. Conversely, a potentially meaningful effect may remain statistically uncertain in a smaller study.

Results should therefore be reported using appropriate effect estimates, measures of uncertainty, and clinical interpretation rather than relying only on whether a statistical threshold was crossed.

Confidence intervals can help indicate the precision of an estimate and the range of effects compatible with the data and statistical assumptions. Their interpretation should also consider the possibility of bias, the clinical relevance of the outcome, and the limitations of the study design.

Average results may conceal important variation. Some patients may obtain substantial benefits while others experience little improvement or greater treatment burden. Exploring these differences can be useful, but subgroup analyses should be planned carefully and interpreted cautiously, particularly when sample sizes are small or analyses were not specified in advance.

For healthcare organizations, the purpose of measuring patient-important outcomes is not to demonstrate that every program is successful. It is to determine whether patients benefit, how meaningful those benefits are, and how confidently the findings can inform clinical decisions.

Reliable Real-World Data Require Attention to Who Is Missing

Real-world evaluations increasingly use information collected during ordinary clinical care.

Electronic medical records, laboratory systems, appointment records, clinical registries, and patient questionnaires can provide valuable information without requiring every observation to be collected through a separate research process.

However, information created for clinical and administrative purposes may not meet all the requirements of a particular research question.

Blood pressure may be measured using different devices or procedures. Follow-up visits may occur at irregular intervals. Some outcomes may be documented only when patients return for care, while others may depend on patient recall or self-reporting.

These differences can influence the interpretation of results.

Patients receiving more intensive follow-up may have more complete records than those who disengage from the service. If the likelihood of observing an outcome is related to a patient's clinical status, treatment, or participation, an analysis limited to complete records may introduce bias.

Missing information should not automatically be treated as evidence that a patient remained stable, improved, or deteriorated. Researchers should examine why data are missing and consider how different assumptions could affect their findings.

Data collected across multiple facilities introduce additional challenges. Clinical definitions, recording practices, coding systems, and measurement intervals may differ. Linking records can also create errors when patient information is incorrectly matched or observation periods are inconsistent.

A research protocol should define the population being evaluated, eligibility criteria, observation period, intervention exposure, data sources, and methods used to determine outcomes. Relevant data-quality checks and approaches to missing information should be considered in advance.

Large datasets are not automatically more reliable. Thousands of records containing systematic errors may provide less credible evidence than a smaller dataset collected according to consistent definitions and a carefully designed protocol.

An equally important question concerns the people represented in those records.

A Lifestyle Medicine intervention may appear successful partly because patients facing the greatest barriers were never enrolled or were not represented in the final analysis.

Sustained participation can be influenced by employment, household income, caregiving responsibilities, transportation, health literacy, digital access, and the availability of suitable healthcare services.

A program delivered only during working hours may be difficult for people with inflexible employment. Patients living far from a healthcare facility may face substantial travel costs. Digital follow-up may be convenient for those with reliable internet access but less accessible to others.

These circumstances matter when evaluating interventions that require repeated appointments, substantial changes in daily routines, or ongoing communication with healthcare professionals.

Researchers should therefore examine how the eligible population relates to those offered the intervention, those who enrolled, those who continued participating, and those whose outcomes were ultimately analyzed.

Differences between these groups can reveal important limitations in program reach and help explain why an intervention is difficult to implement.

This does not mean that every study must represent the entire Vietnamese population. A focused evaluation of a clearly defined clinical group may provide valuable evidence. The important requirement is to describe the population accurately and avoid extending conclusions beyond what the data support.

Equity should be considered as part of both implementation and research interpretation. An intervention that benefits motivated, well-supported patients may still be clinically useful, but its results should not be presented as evidence that the same model will work equally well among people facing greater social or practical barriers.

Safety and Concurrent Medical Treatment Must Be Evaluated

Lifestyle interventions are sometimes assumed to be inherently safe because they involve changes in daily behaviors rather than invasive procedures or medications.

This assumption is too broad for responsible clinical evaluation.

Substantial dietary changes, increased physical activity, or weight reduction may affect medication requirements or introduce risks for particular patients.

For example, patients receiving insulin or other glucose-lowering medications associated with hypoglycemia may require closer monitoring when dietary intake or physical activity changes substantially. Individuals with cardiovascular disease, frailty, significant functional limitations, or other clinical conditions may need individualized assessment before beginning intensive exercise.

The appropriate precautions depend on the intervention and the patient's clinical circumstances.

Researchers should document clinically relevant harms, unintended consequences, treatment burden, and changes in concurrent medical care where these may influence the interpretation of results.

Medication adjustments deserve particular attention because they may be necessary to protect patients and maintain appropriate treatment while also influencing measured clinical outcomes.

From a methodological perspective, researchers should not automatically treat every medication change as an ordinary confounder that must be removed through statistical adjustment.

In some studies, treatment adjustments may be part of the intended clinical pathway. In others, they may occur because a patient's health has improved or deteriorated after the intervention began. Adjusting for variables that arise after the intervention starts can sometimes distort the effect the study intends to estimate.

The appropriate analytical approach depends on the causal question, the role of concurrent treatment, and the assumptions underlying the research design.

Clinically, fewer medications should not automatically be interpreted as a favorable Lifestyle Medicine outcome. Medication reduction may be appropriate for some patients but unnecessary or unsafe for others.

Discontinuing prescribed treatment without appropriate professional guidance should never be counted as evidence of successful lifestyle-based care simply because medication use has decreased.

Research procedures must not interfere with necessary clinical treatment. If clinically important concerns arise during an evaluation, healthcare professionals must respond according to the patient's needs and applicable clinical requirements.

Scientific rigor is important, but it does not override the responsibility to provide safe and appropriate care.

Understanding Resources Without Assuming Cost Savings

Clinical effectiveness is only one factor in deciding whether a Lifestyle Medicine program should become part of routine healthcare.

Organizations also need to understand the resources required to deliver and maintain the intervention.

A program may require staff training, additional consultations, multidisciplinary coordination, educational materials, administrative support, or digital infrastructure. Patients may incur transportation expenses, lose working time, or face additional costs associated with participation.

These resources should be considered alongside the benefits observed.

It is important not to assume that better clinical outcomes automatically produce lower healthcare expenditure.

An intervention can be clinically beneficial and cost-effective without reducing total spending. It may also increase short-term costs while generating benefits that become apparent only over a longer period.

The economic perspective matters. Costs borne by a healthcare organization may differ from those experienced by patients, insurers, or society.

For an initial feasibility or implementation study, the most useful task may be to document the resources required rather than attempt a comprehensive economic evaluation without sufficient data.

Formal claims about cost-effectiveness, cost savings, or budget impact require appropriate methods, transparent assumptions, and a clearly defined analytical perspective and time horizon.

For healthcare leaders, sustainability also involves considering whether the service can continue when pilot funding, additional staffing, or external technical support is no longer available.

A program should not be considered ready for expansion solely because its clinical outcomes are favorable. Its benefits, resource requirements, and implications for other clinical services should be evaluated together.

A Hypothetical Vietnamese Study: Evaluating a Hypertension Lifestyle Program

The outpatient program described at the beginning illustrates how these methodological considerations can be brought together.

Suppose several Vietnamese clinics want to evaluate a structured Lifestyle Medicine pathway for adults receiving treatment for hypertension. The pathway combines individualized dietary counseling, physical activity support, and scheduled follow-up alongside appropriate medical management.

The first task is to describe the intervention and determine what question the clinics want to answer.

If the initial concern is whether the service can be delivered under routine conditions, a feasibility evaluation may be appropriate. Investigators would define eligibility criteria, document how patients are recruited, assess whether professionals can provide the planned consultations, and determine whether follow-up measurements can be collected reliably.

The evaluation might reveal that some clinics have insufficient time for individualized counseling, that patients have difficulty attending appointments, or that blood pressure measurements are not recorded consistently.

These findings would be useful even before clinical effectiveness is examined. They could inform changes to the delivery model and improve the feasibility of a subsequent study.

If the next question concerns whether the program produces additional clinical benefit compared with routine care, the investigators would need an appropriate comparative design.

Depending on resources, staffing arrangements, and practical feasibility, this could involve individual randomization, cluster randomization, or a carefully designed quasi-experimental comparison.

The protocol should specify the study population, comparison condition, primary and secondary outcomes, follow-up period, and analytical methods. It should also address medication adjustments, missing data, potential differences between clinics, and the clinical responsibilities of participating professionals.

Implementation outcomes would provide complementary information. Investigators could examine whether essential components were delivered, whether referrals were completed, what proportion of eligible patients participated, and why some patients discontinued follow-up.

Suppose the intervention clinics report lower average blood pressure after six months.

If a credible comparison group experiences a similar improvement during the same period, the findings would provide less support for a substantial additional benefit from the new pathway than the before-and-after results alone might suggest.

If the intervention group improves more than an appropriate comparator, the strength of the causal conclusion would depend on the study design, quality of the measurements, analytical methods, and potential remaining bias.

Implementation findings would then help place the clinical results in context.

Perhaps some clinics delivered the planned counseling consistently while others experienced substantial interruptions. Perhaps patient participation was high but the intervention required more staff time than anticipated. Alternatively, the program may have produced encouraging outcomes among participants while reaching only a small proportion of eligible patients.

The findings could help determine whether the intervention should be continued, modified, studied further, or considered for broader implementation.

A decision to expand would require attention to both the credibility of the clinical effects and the feasibility of reproducing the program in other settings. The investigators would also need to examine whether patients experienced meaningful benefits and whether the intervention created additional risks or burdens.

This example is hypothetical and is intended to illustrate the relationship between research questions, study designs, clinical outcomes, and implementation. It does not describe an actual Vietnamese study, an approved research protocol, or a recommendation that one particular design should be applied universally.

Any real project would require appropriate scientific, clinical, institutional, and ethical assessment before implementation.

Distinguishing Quality Improvement From Biomedical Research in Viet Nam

Healthcare organizations routinely monitor clinical outcomes and conduct quality-improvement activities to make care safer and more reliable.

A department may review whether patients receive planned follow-up, whether documentation is complete, or whether a revised referral procedure improves continuity of care. Such activities may form part of ordinary clinical governance rather than formal biomedical research.

Research may have a different purpose, particularly when investigators undertake a systematic study to estimate comparative effectiveness or generate knowledge intended to inform practice beyond the immediate service.

However, the boundary between research and quality improvement is not always straightforward.

An improvement initiative may also include research components, especially when it introduces additional procedures, involves randomization, uses comparison groups, or seeks to answer questions extending beyond routine service monitoring.

The two categories should not automatically be treated as mutually exclusive, and assigning a project a particular label does not determine all its ethical or regulatory obligations.

In Viet Nam, Ministry of Health Circular No. 43/2024/TT-BYT, dated December 12, 2024, and effective February 1, 2025, regulates the establishment, organization, and operation of ethics committees in biomedical research at national and institutional levels.[10]

The Circular sets out provisions concerning the organization, responsibilities, and activities of these ethics committees within its regulatory scope.

It should not be interpreted as requiring every routine clinical dashboard or internal quality-monitoring activity to undergo the same review process as an interventional clinical study.

Conversely, describing an activity as quality improvement does not remove ethical or regulatory requirements that otherwise apply.

Before initiating a project, the responsible institution should examine its purpose, the procedures involved, whether additional interventions or research-related activities will affect patient care, whether identifiable patient information will be used, and whether ethical review, institutional authorization, participant information, or consent is required.

Where the classification or applicable requirements are uncertain, the determination should be made through appropriate institutional and regulatory processes rather than assumed by the project team.

Any legally permissible waiver or modification of research-related informed-consent requirements must be considered through the appropriate authorized process and under the applicable conditions.

The protection of research participants also requires attention to foreseeable risks, participation burden, vulnerable populations, recruitment fairness, and the management of adverse events.

The World Medical Association's 2024 revision of the Declaration of Helsinki provides an important international ethical reference for medical research involving human participants, including research involving identifiable human data or material.[22]

Its principles emphasize the protection of participants' rights and interests, scientific integrity, appropriate ethical review, informed consent, and responsible research conduct. However, international ethical declarations do not replace the specific legal and institutional requirements applicable in Viet Nam.

Where a Lifestyle Medicine program involves regulated medical examination and treatment activities, the applicable requirements of Viet Nam's Law on Medical Examination and Treatment and its implementing regulations remain relevant. Law No. 15/2023/QH15, as amended, is reflected in Consolidated Document No. 26/VBHN-VPQH, issued by the Office of the National Assembly on February 26, 2026.[11]

International Lifestyle Medicine training, professional competencies, or research frameworks do not independently authorize professionals to perform clinical activities beyond their lawful scope of practice in Viet Nam.

Scientific quality and ethical responsibility are closely connected. A study that exposes participants to additional risks or burdens without a reasonable prospect of answering its research question may be difficult to justify, regardless of how promising the intervention appears.

Health Data Protection Is Part of Research Quality

Real-world research increasingly relies on information collected through electronic medical records, laboratory systems, patient questionnaires, digital monitoring platforms, and administrative databases.

These sources can improve the feasibility of healthcare evaluation, but their use introduces important legal and organizational responsibilities.

Access to information for clinical care does not automatically establish unrestricted authority to use, disclose, or transfer the same information for research.

Researchers and healthcare organizations must consider the intended purpose of data processing, the applicable legal basis, patient rights, institutional responsibilities, and the safeguards required for the information involved.

Viet Nam's Law on Personal Data Protection No. 91/2025/QH15, effective January 1, 2026, establishes the national legal framework for personal data protection.[12]

Decree No. 356/2025/NĐ-CP, also effective January 1, 2026, provides further requirements concerning the implementation of that law.[13]

Decree No. 102/2025/NĐ-CP, effective July 1, 2025, regulates the management of digital health data within its defined scope.[14]

Decree No. 330/2026/NĐ-CP, effective August 19, 2026, establishes administrative sanctions for specified violations involving cybersecurity and personal-data protection.[15]

These instruments should be considered alongside other applicable legal provisions and institutional requirements according to the nature of the proposed activity.

For research teams, responsible data governance begins with determining which information is necessary and why it is needed.

The protocol should address how information will be collected, who may access it, how records will be linked, where data will be stored, how long they will be retained, and whether they will be disclosed to other organizations.

Special care is needed when information from multiple sources is combined. Removing names or identification numbers may reduce privacy risks, but it does not necessarily eliminate the possibility of identifying individuals through combinations of variables or linkage with other records.

Anonymization and pseudonymization should not be treated as interchangeable concepts. The appropriate safeguards and legal treatment depend on the actual characteristics of the data and the applicable requirements.

Multicenter research and international collaborations may create additional responsibilities when information is shared between institutions or transferred across national borders.

Consent requirements also need careful interpretation. Consent may be required in particular circumstances, while applicable law may provide other lawful bases or specific exceptions. The relevant requirements should be determined for the actual research and data-processing activities rather than assumed to be identical in every case.

An ethics committee's decision concerning research consent should not automatically be interpreted as removing separate obligations under personal-data protection law.

Data governance is therefore more than an administrative requirement. It supports patient confidentiality, institutional trust, reliable data handling, and the scientific integrity of the research itself.

Transparent Reporting Makes Findings More Useful

A well-designed evaluation can still be difficult to interpret if its methods and findings are incompletely reported.

International reporting guidelines provide useful resources for explaining what researchers planned, what they conducted, what they observed, and how the results should be interpreted.

The SPIRIT 2025 statement provides updated guidance for the content of randomized trial protocols, while CONSORT 2025 addresses reporting randomized trial results.[16,17]

Both statements were published in 2025 and reflect developments in research methodology, transparency, and reporting.

For observational studies, the STROBE statement remains an important reference. The RECORD extension provides additional guidance for studies using routinely collected health data.[18,19]

The Standards for Reporting Implementation Studies, or StaRI, address reporting of implementation research, including the distinction between a clinical intervention and the strategy used to implement it.[20]

SQUIRE 2.0 provides guidance for reporting systematic healthcare improvement work, particularly the rationale, context, methods, and learning associated with improvement initiatives.[21]

TIDieR complements these resources by helping researchers describe interventions and comparison conditions sufficiently for readers to understand what was delivered.[3]

These guidelines have different purposes and should be selected according to the study design and reporting objectives. Not every evaluation needs to apply every checklist.

Reporting guidance also cannot repair fundamental methodological weaknesses after a study has been completed.

A checklist may encourage researchers to disclose the limitations of an uncontrolled study, but it cannot establish an appropriate comparison group retrospectively. It can prompt investigators to describe missing data, but it cannot automatically remove the bias created by incomplete follow-up.

The credibility of a study still depends on how the research was designed, conducted, analyzed, and interpreted.

Prospective planning, clearly defined outcomes, appropriate documentation of methodological changes, and transparent disclosure of funding and potential conflicts of interest can further strengthen confidence in the findings.

Prospective registration of eligible clinical trials and access to appropriate protocol information may also improve transparency, subject to applicable requirements and legitimate protections concerning confidential information.

Nor does adherence to an international reporting guideline establish that a study has received ethical approval, met Vietnamese legal requirements, or obtained accreditation from any professional or regulatory organization.

Transparent reporting makes evidence easier to evaluate. It allows readers to understand what conclusions are supported, which uncertainties remain, and what further investigation may be necessary.

Using Real-World Evidence to Make Better Healthcare Decisions

A useful evaluation does not always produce a positive result.

Some studies show that an intervention can be delivered but provides limited additional clinical benefit. Others reveal favorable outcomes accompanied by substantial resource requirements. A program may work well among selected participants while reaching only a small proportion of the patients who could potentially benefit.

These findings can all contribute to better healthcare decisions when the methods are sound and the limitations are reported clearly.

A program that performs poorly should not automatically be abandoned without examining whether its essential components were delivered appropriately. At the same time, a program reporting favorable outcomes should not be expanded without considering whether those outcomes are credible, whether patients experienced meaningful benefits, and whether the organization can sustain the service safely.

Negative or inconclusive results are not necessarily research failures. They may prevent resources from being committed to ineffective approaches or reveal changes needed before further evaluation.

For Viet Nam, strengthening real-world Lifestyle Medicine research does not require every healthcare organization to replicate large international trials.

Feasibility assessments, descriptive evaluations, comparative studies, pragmatic trials, implementation research, and structured quality-improvement activities can each make a contribution when their purposes are clear and their findings are interpreted within the limits of their methods.

The most valuable local questions will often concern how established evidence can be translated into Vietnamese healthcare, which organizational conditions are necessary, what patients actually experience, and whether the benefits can be achieved across different clinical settings without introducing unacceptable risks or burdens.

The role of the Vietnam Lifestyle Medicine Alliance (VLMA) is to support evidence-based professional education, scientific knowledge exchange, and informed discussion about responsible research and implementation. This includes encouraging healthcare professionals and researchers to understand the strengths and limitations of different evaluation methods.

Such activities do not establish a separate research approval system, create nationally binding methodological standards, or replace the responsibilities of authorized institutions and regulatory bodies.

Ultimately, the value of real-world evaluation lies in the quality of the decisions it supports.

A clinically promising Lifestyle Medicine program deserves more than an encouraging before-and-after comparison. It deserves an evaluation capable of explaining what was delivered, who participated, which outcomes changed, how confidently those changes can be attributed to the intervention, and what would be required to achieve similar results elsewhere.

This approach can help healthcare organizations recognize genuinely useful interventions, improve those that encounter implementation difficulties, and avoid expanding programs whose benefits remain uncertain.

For patients, it can provide a stronger basis for understanding what a program may realistically achieve and what responsibilities or burdens participation may involve. For clinicians, it can help distinguish evidence-based care from apparently successful activities that have not been adequately evaluated. For healthcare leaders, it can support more informed decisions about resources, service development, and long-term sustainability.

That is how real-world evidence can help make Lifestyle Medicine more credible, clinically meaningful, and sustainable within Vietnamese healthcare.

References and Further Reading
  1. Vos RC, van Osch LADM, van Bilsen JHM, et al. Evidence-based implementation of lifestyle medicine in healthcare practice: a research agenda. Family Medicine and Community Health. 2025;13(3):e003324. doi:10.1136/fmch-2025-003324.

  2. Skivington K, Matthews L, Simpson SA, et al. A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. BMJ. 2021;374:n2061. doi:10.1136/bmj.n2061.

  3. Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. doi:10.1136/bmj.g1687.

  4. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015;350:h2147. doi:10.1136/bmj.h2147.

  5. Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. American Journal of Epidemiology. 2016;183(8):758–764. doi:10.1093/aje/kwv254.

  6. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness research and implementation research to enhance public health impact. Medical Care. 2012;50(3):217–226. doi:10.1097/MLR.0b013e3182408812.

  7. Proctor E, Silmere H, Raghavan R, et al. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Administration and Policy in Mental Health. 2011;38:65–76. doi:10.1007/s10488-010-0319-7.

  8. Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. American Journal of Public Health. 1999;89(9):1322–1327. doi:10.2105/AJPH.89.9.1322.

  9. Damschroder LJ, Reardon CM, Widerquist MAO, Lowery J. The updated Consolidated Framework for Implementation Research based on user feedback. Implementation Science. 2022;17:75. doi:10.1186/s13012-022-01245-0.

  10. Ministry of Health of Viet Nam. Circular No. 43/2024/TT-BYT, dated December 12, 2024, regulating the establishment, organization, and operation of Ethics Committees in Biomedical Research. Effective February 1, 2025.

  11. National Assembly of Viet Nam. Law on Medical Examination and Treatment No. 15/2023/QH15, dated January 9, 2023, as amended. See also Consolidated Document No. 26/VBHN-VPQH, issued by the Office of the National Assembly on February 26, 2026, and applicable implementing regulations.

  12. National Assembly of Viet Nam. Law on Personal Data Protection No. 91/2025/QH15, dated June 26, 2025. Effective January 1, 2026.

  13. Government of Viet Nam. Decree No. 356/2025/NĐ-CP, dated December 31, 2025, detailing selected provisions and implementation measures of the Law on Personal Data Protection. Effective January 1, 2026.

  14. Government of Viet Nam. Decree No. 102/2025/NĐ-CP, dated May 13, 2025, on Health Data Management. Effective July 1, 2025.

  15. Government of Viet Nam. Decree No. 330/2026/NĐ-CP, dated August 19, 2026, on Administrative Sanctions in Cybersecurity and Personal Data Protection. Effective August 19, 2026.

  16. Chan AW, Boutron I, Hopewell S, et al. SPIRIT 2025 statement: updated guideline for protocols of randomised trials. BMJ. 2025;389:e081477. doi:10.1136/bmj-2024-081477.

  17. Hopewell S, Chan AW, Collins GS, et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ. 2025;389:e081123. doi:10.1136/bmj-2024-081123.

  18. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLOS Medicine. 2007;4(10):e296. doi:10.1371/journal.pmed.0040296.

  19. Benchimol EI, Smeeth L, Guttmann A, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLOS Medicine. 2015;12(10):e1001885. doi:10.1371/journal.pmed.1001885.

  20. Pinnock H, Barwick M, Carpenter CR, et al. Standards for Reporting Implementation Studies (StaRI) Statement. BMJ. 2017;356:i6795. doi:10.1136/bmj.i6795.

  21. Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D. SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process. BMJ Quality & Safety. 2016;25(12):986–992. doi:10.1136/bmjqs-2015-004411.

  22. World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Participants. JAMA. 2025;333(1):71–74. Adopted in its revised form in October 2024. doi:10.1001/jama.2024.21972.

Editorial, Research Ethics and Regulatory Note

This article is published by the Vietnam Lifestyle Medicine Alliance (VLMA) for professional education, scientific knowledge exchange, and discussion of responsible approaches to evaluating evidence-based Lifestyle Medicine in Vietnamese healthcare.

It provides an educational review of selected international research methods, implementation science frameworks, reporting guidelines, and relevant Vietnamese regulatory considerations. It is not a Vietnamese national clinical practice guideline, an officially approved research methodology standard, a legally binding research ethics determination, a regulatory approval, or an authoritative legal opinion.

Descriptions of possible research designs, comparative evaluations, pragmatic trials, implementation assessments, and hypothetical clinical programs are illustrative. They are not presented as validated or approved research protocols, and they do not imply that VLMA has conducted, authorized, or endorsed any particular clinical study.

The selection of a research design, clinical intervention, evaluation method, or data collection process must reflect the actual purpose of the project, the population involved, scientific requirements, available resources, and applicable Vietnamese laws and institutional policies.

Research involving human participants, clinical interventions, identifiable health information, or changes to patient care must undergo the ethical, regulatory, and institutional processes applicable to the specific activity. Classification as quality improvement, service evaluation, or research does not independently determine or remove those requirements.

International frameworks such as SPIRIT, CONSORT, STROBE, RECORD, StaRI, SQUIRE, TIDieR, RE-AIM, and CFIR are methodological, implementation, or reporting resources with distinct purposes. Their use does not independently establish clinical effectiveness, scientific validity, ethical approval, professional authorization, or regulatory compliance.

Healthcare professionals involved in Lifestyle Medicine interventions or research must remain within their lawful professional scope and comply with applicable requirements concerning patient safety, informed participation, medical records, confidentiality, and personal-data protection.

VLMA does not independently authorize biomedical research, approve clinical trials, grant healthcare practice licenses, establish national research ethics requirements, or certify research programs for regulatory purposes.

The scientific and regulatory materials referenced in this article were reviewed through November 21, 2026. Healthcare organizations and researchers should verify applicable laws, institutional requirements, and regulatory conditions before initiating any clinical or research activity.

Vietnam Lifestyle Medicine Alliance

Evidence-Based Lifestyle Medicine for Viet Nam.

Contact

contact@vlma.org

Saigon Paragon Building, No. 3 Nguyen Luong Bang Street, Tan My Ward, HCMC

+84 909 228 476

+84 84 9999 911

© 2025 - 2026. Vietnam Lifestyle Medicine Alliance. All rights reserved.

A physician-led professional platform advancing Lifestyle Medicine through education, collaboration, research, and responsible implementation.

VLMA is operated by Vietnam Lifestyle Medicine Alliance Company Limited, Enterprise Registration Number 0318902666.

VLMA is a Sister Organization of the Lifestyle Medicine Global Alliance and a Member Organization of the Planetary Health Alliance.

VLMA is not a medical service provider and does not issue medical licenses or IBLM certification.